# The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration

> **NCT06994312** · NA · NOT_YET_RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 282 (estimated)

## Conditions studied

- Sepsis-induced Coagulopathy (SIC)

## Interventions

- **DRUG:** Nafamostat Mesylate
- **DRUG:** sodium citrate

## Key facts

- **NCT ID:** NCT06994312
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2028-05-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 282 (ESTIMATED)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06994312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06994312, "The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06994312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*